Lv12
32 积分 2026-03-02 加入
Haschek and Rousseaux's Handbook of Toxicologic Pathology
6小时前
求助中
Preliminary Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors
1天前
已完结
Discovery and Characterization of a First-In-Class HCK/BTK PROTAC DFCI-002-06 for the Treatment of MYD88 Mutated B Cell Malignancies
1天前
已完结
Safety considerations for cereblon-recruiting targeted protein degraders
8天前
已完结
Identification and preclinical characterization of a novel and potent poly (ADP-ribose) polymerase (PARP) inhibitor ZYTP1
9天前
已完结
Use of cyclodextrins as excipients in pharmaceutical products: why not in extemporaneous preparations?
27天前
已关闭
Use of cyclodextrins as excipients in pharmaceutical products: why not in extemporaneous preparations?
27天前
已关闭
Cyclodextrin-based formulations for pediatric patients: pharmaceutical prospectives and toxicological evaluation
28天前
已完结
Species Selection for Pharmaceutical Toxicity Studies
1个月前
已完结
Targeted protein degradation: from mechanisms to clinic
1个月前
已完结
皖公网安备34019202002308
